ISSN 1662-4009 (online)

ey0019.6-15 | Gender Incongruence: Wider impacts of gender affirming hormone (GAH) treatments | ESPEYB19

6.15. Self-perception of transgender adolescents after gender-affirming treatment: a follow-up study into young adulthood

M Arnoldussen , der Miesen AIR van , WS Elzinga , AE Alberse , A Popma , TD Steensma , Vries ALC de

LGBT Health. 2022 May-Jun;9(4):238-246. PMID:35475663, doi: 10.1089/lgbt.2020.0494. Brief Summary: This study reports changes in wellbeing and quality of life in 70 adolescents (49 transgender men and 21 transgender women) from the Amsterdam Center for Expertise on Gender Dysphoria. It finds evidence of improvements in functioning on GAH. The purpose of gender-affirming ...

ey0017.8-15 | New Concerns | ESPEYB17

8.15. Altered gray matter structure and white matter microstructure in patients with congenital adrenal hyperplasia: Relevance for working memory performance

Westeinde A Van’t , L Karlsson , Sandberg M Thomsen , A Nordenstrom , N Padilla , S Lajic

To read the full abstract: Cereb Cortex. 2020; 30(5): 2777–2788. PMID: 31819952.Congenital adrenal hyperplasia (CAH), most commonly caused by 21-hydroxylase deficiency, is an autosomal recessively inherited life-threatening impairment in cortisol and, in the severe salt wasting form, aldosterone synthesis. The implementation of neonatal screening programs for CAH and the continuous imp...

ey0017.9-8 | New Fertility Preservation Strategies: Lights and Shadows | ESPEYB17

9.8. Does co-transplantation of mesenchymal and spermatogonial stem cells improve reproductive efficiency and safety in mice?

P Kadam , E Ntemou , J Onofre , D Van Saen , E Goossens

To read the full abstract: Stem Cell Res Ther. 2019 Oct 22;10(1):310. ellen.goossens@vub.beInfertility due to spermatogonial stem cell (SSC) loss is one of the major late adverse effects related to both chemotherapy and radiotherapy, and several researchers are now focusing on the development of new techniques to preserve germ cells.Semen sample storage is not feasible in prepuber...

ey0016.6-16 | New Working Hypotheses in Transgender | ESPEYB16

6.16. Prevalence of the wish to be of the opposite gender in adolescents and adults with autism spectrum disorder

Miesen AIR van der , H Hurley , AM Bal , ALC de Vries

Arch Sex Behav. 2018 Nov;47(8):2307–2317.doi: 10.1007/s10508-018-1218-3. PubMed ID: 29736809An increased incidence of autism spectrum disorder (ASD) among adolescents and adults with gender dysphoria has been reported in many studies. This paper describes one of the rare studies taking an opposite approach, by investigating the self-reported wish to be of the ...

ey0016.15-8 | (1) | ESPEYB16

15.8. Variation in the heritability of child body mass index by obesogenic home environment

S Schrempft , CHM van Jaarsveld , A Fisher , M Herle , AD Smith , A Fildes , CH Llewellyn

To read the full abstract: JAMA Pediatr 2018;172:1153–1160.This paper describes a gene-environment interaction twin study in 925 UK families (1850 twins). The heritability of childhood BMI was calculated by comparing the concordance in BMI at mean age 4.1 years between monozygous and dizygous twins; heritability was much higher among more obesogenic households (h2=8...

ey0015.4-3 | Important for clinical practice | ESPEYB15

4.3 Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study

M van der Steen , GF Kerkhof , CCJ Smeets , ACS Hokken-Koelega

To read the full abstract: Lancet Diabetes Endocrinol 2017;5:975-985Whereas most SGA children experience spontaneous catch-up growth leading to the achievement of normal adult height, approximately 10% remain short and are candidates for GH therapy. SGA subjects have increased cardio-metabolic disease risk [17] and the effects of GH treatment on blood...

ey0015.6-8 | New treatments | ESPEYB15

6.8 Efficacy and Safety of Pubertal Induction Using 17β-Estradiol in Transgirls

SE Hannema , SEE Schagen , PT Cohen-Kettenis , HA Delemarre-van de Waal

To read the full abstract: J Clin Endocrinol Metab. 2017 Jul ;102 (7):2356-2363[Comments on 6.6, 6.7 and 6.8] These 3 papers deal with endocine pharmacological treatment of patients with GD.The first article by Chew et al. (6.6), from Australia, systematically reviews different pharmacolo...

ey0015.8-20 | Reviews | ESPEYB15

8.20 Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia

N1 Rensen , RJ Gemke , EC van Dalen , J Rotteveel , GJ Kaspers

To read the full abstract: Cochrane Database Syst Rev. 2017; 11:CD008727Glucocorticoids (GCs), such as prednisone (prednisolone) or dexamethasone, are essential agents in the treatment of acute lymphoblastic leukemia (ALL), the most common malignancy in childhood. They are administered in highly supraphysiologic doses in cyclic courses. Thus, every pediatric endocrinologist fears HPA axi...

ey0020.2-4 | Important for Clinical Practice | ESPEYB20

2.4. Childhood growth hormone treatment and metabolic and cardiovascular risk in adults born small for gestational age after growth hormone cessation in the Netherlands: a 12-year follow-up study

WJ Goedegebuure , M van der Steen , CCJ Smeets , ACS Hokken-Koelega

Brief summary: In this longitudinal study, the authors investigated the metabolic and cardiovascular health profile of 167 adults born SGA and previously treated with rhGH during a period of 12 years after therapy discontinuation. No relevant differences were found in treated SGA subjects compared with untreated SGA adults or adults born appropriate for gestational age (AGA), thus suggesting long-term metabolic and cardiovascular safety of rhGH treatment in short SGA children....

ey0020.4-12 | Changes to Growth Patterns | ESPEYB20

4.12. Just as tall on testosterone; a neutral to positive effect on adult height of GnRHa and testosterone in trans boys

LA Willemsen , LS Boogers , CM Wiepjes , DT Klink , ASP van Trotsenburg , M den Heijer , SE Hannema

Brief summary: This paper investigated the effect of pubertal suppression with GnRHa and gender affirming treatment with testosterone on the growth and final height of transgender boys. They found no negative effects, and even possibly a slight boost to adult height in comparison with target and predicted heights for birth-registered sex.One of the concerning features of transgender males is being able to identify with their cisgender peers in stature. I...